Searched for
GLP1 PENS
Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...- Be stock-specific, look for bargains: Daljeet Kohli on Nifty at 24,000 and top sector picksMarket expert Daljeet Kohli advises investors to focus on quality stocks at discounted prices, rather than the Nifty's movement. He highlig...
- Dr Reddy’s launches generic Semaglutide injection, popular weight-loss drug, in CanadaDr Reddy's Laboratories has launched its generic Semaglutide injection in Canada. This marks a significant step for the company in providin...
- Semaglutide race: Torrent grabs 38% market shareOver a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...
- Dr Reddy’s Laboratories receives approval from Health Canada for its generic semaglutide injectionDr Reddy's Laboratories has achieved a significant milestone. Health Canada has approved its generic semaglutide injection. This makes Dr R...
- Dr Reddy's gets Health Canada nod for generic semaglutide injectionDr Reddy's Laboratories has secured market authorization from Health Canada for its generic semaglutide injection. This marks a significant...
- Time to buy? Sunny Agrawal finds best picks across banking, pharma, capital markets & infrastructureIndian stock markets present attractive opportunities now. Investors with an 18-month outlook should consider deploying funds, especially i...
- Mounjaro sales dip amid price war as semaglutide generics gain groundMounjaro, the star pharmaceutical from Eli Lilly, is experiencing a downturn in sales across India. This slump can be attributed to competi...
- Market bets on Aurobindo as Europe, US sales show uptickAurobindo Pharma stock is performing well. Sales in Europe are improving. New products are launching in the US. The company is also develop...
- Novo Nordisk cuts Ozempic and Wegovy prices by up to 48% as GLP-1 competition intensifies in IndiaNovo Nordisk has significantly slashed prices for Ozempic and Wegovy in India, reducing them by 36% and 48% respectively, to enhance patien...
- Rs 12,000 crore magic pill race begins to shrink India's pot bellies. Which pharma stocks will win GLP-1 war?India's GLP-1 market is set for a massive boom. Following patent expiry, generic versions of semaglutide are launching at significantly low...
- Price alone won't push weight-loss, diabetes drug semaglutide sales: DoctorsLeading drugmakers including Sun Pharmaceuticals, Dr Reddy’s Laboratories, Zydus Lifesciences, Natco Pharma, Eris Lifesciences, USV, Glenma...
- Dr. Reddy’s Lab launches India’s first DCGI-approved Semaglutide injection for Type 2 DiabetesDr. Reddy's Laboratories has launched Obeda, a generic semaglutide injection for Type 2 diabetes, becoming the first Indian company to rece...
- Weight-loss drug boom: Will cheaper Ozempic generics shake up India’s fitness and nutrition industry?The rise of GLP-1 weight-loss drugs such as Ozempic is posing a challenge to the fitness industry, with cheaper generic versions expected t...
- Abbott signs pact with Novo Nordisk to offer semaglutideSemaglutide, sold by Novo Nordisk under brands such as Ozempic and Wegovy, goes off patent on March 21 in India. A raft of Indian generic d...
- Narendra Solanki sees select opportunities in metals, GLP-1 and solar playsAmid global uncertainty, market expert Narendra Solanki advises theme-based investing. He highlights opportunities in specific metals like ...
- Emcure Pharma launches second Novo drug for weight managementEmcure Pharmaceuticals has taken a bold step in the realm of health and wellness by introducing Poviztra, a breakthrough in weight manageme...
- What are GLP-1 medicines? Do they help with weight loss and diabetes, and what are their side effects?GLP-1 medications are prescription treatments used in the UK to manage type 2 diabetes and, in certain cases, medically supervised weight l...
- Eris Lifesciences eyes ‘good’ share in semaglutide generics, says COOEris Lifesciences plans to lead in generic semaglutide drugs. The patent for Novo Nordisk's drug expires in India in March 2026. Eris aims ...
- Novo to launch Victoza in Japan in JuneDenmark's Novo Nordisk said it would launch its potential blockbuster drug Victoza in Japan this month.
Load More
